BeyondSpring (BYSI) to Release Quarterly Earnings on Tuesday

BeyondSpring (NASDAQ:BYSI) is expected to be issuing its Q4 2025 results before the market opens on Tuesday, May 12th. Analysts expect the company to announce earnings of ($0.54) per share and revenue of $8.7670 million for the quarter. Parties are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, April 16, 2026 at 9:30 AM ET.

BeyondSpring (NASDAQ:BYSI) last released its quarterly earnings data on Wednesday, March 25th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.49.

BeyondSpring Trading Down 5.0%

Shares of BYSI stock traded down $0.08 during mid-day trading on Tuesday, reaching $1.44. The stock had a trading volume of 22,946 shares, compared to its average volume of 23,926. The stock’s 50-day moving average price is $1.60 and its two-hundred day moving average price is $1.72. BeyondSpring has a 52-week low of $1.21 and a 52-week high of $3.44. The firm has a market capitalization of $59.01 million, a PE ratio of -9.57 and a beta of 0.41.

Hedge Funds Weigh In On BeyondSpring

A hedge fund recently raised its stake in BeyondSpring stock. Geode Capital Management LLC lifted its stake in shares of BeyondSpring Inc. (NASDAQ:BYSI) by 951.4% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 256,212 shares of the company’s stock after buying an additional 231,844 shares during the quarter. Geode Capital Management LLC owned about 0.64% of BeyondSpring worth $603,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 40.29% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (d+)” rating on shares of BeyondSpring in a research report on Friday, March 27th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, BeyondSpring has a consensus rating of “Sell”.

About BeyondSpring

BeyondSpring Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapies for oncology. Headquartered in Suzhou, China, with corporate operations in New York, the company leverages a versatile drug discovery platform to advance targeted treatments designed to improve outcomes for patients with cancer. BeyondSpring’s pipeline emphasizes agents that modulate the tumor microenvironment and enhance immune response, with an aim to address key unmet needs in supportive care and tumor control.

The company’s lead candidate, plinabulin, is a small-molecule vascular disrupting agent that also exhibits immunomodulatory activity.